Cargando…
Role of Vesicular Monoamine Transporter 2 Inhibitors in Tardive Dyskinesia Management
Tardive dyskinesia (TD) is a distressing and disabling movement disorder that occurs with the use of chronic neuroleptic medications. TD is defined as involuntary athetoid or choreiform movements of head, trunk or limbs. Tongue, lower face, jaw, and extremities are commonly involved but pharyngeal,...
Autores principales: | Sreeram, Venkatesh, Shagufta, Shanila, Kagadkar, Faisal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802812/ https://www.ncbi.nlm.nih.gov/pubmed/31641566 http://dx.doi.org/10.7759/cureus.5471 |
Ejemplares similares
-
(+)-9-Trifluoroethoxy-α-Dihydrotetrabenazine as a Highly Potent Vesicular Monoamine Transporter 2 Inhibitor for Tardive Dyskinesia
por: Wang, Wenyan, et al.
Publicado: (2021) -
Increasing Abnormal Involuntary Movement Scale (AIMS) Screening for Tardive Dyskinesia in an Outpatient Psychiatry Clinic: A Resident-Led Outpatient Lean Six Sigma Initiative
por: Chakrabarty, Arindam C, et al.
Publicado: (2023) -
NBI‐98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double‐blind, placebo‐controlled study
por: O'Brien, Christopher F., et al.
Publicado: (2015) -
METOCLOPRAMIDE IN TARDIVE DYSKINESIA
por: Hemanani, T.J., et al.
Publicado: (1983) -
Clinical Evolution of Tardive Cervical Dystonia from Antecollis to Retrocollis
por: Costa, Octávia, et al.
Publicado: (2023)